Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID.

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-08-07 eCollection Date: 2024-01-01 DOI:10.1177/17562848241265776

Bénédicte Caron, Philippe Seksik, Anthony Buisson, Pauline Wils, Guillaume Savoye, Carmen Stefanescu, David Laharie, Lucas Guillo, Vered Abitbol, Joelle Bonnet, Romain Altwegg, Lucine Vuitton, Driffa Moussata, Arnaud Bourreille, Amélie Biron, Cyrielle Gilletta, Mathurin Fumery, Stephane Nahon, Stephane Nancey, Houda Camara, Laurent Peyrin-Biroulet

{"title":"Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID.","authors":"Bénédicte Caron, Philippe Seksik, Anthony Buisson, Pauline Wils, Guillaume Savoye, Carmen Stefanescu, David Laharie, Lucas Guillo, Vered Abitbol, Joelle Bonnet, Romain Altwegg, Lucine Vuitton, Driffa Moussata, Arnaud Bourreille, Amélie Biron, Cyrielle Gilletta, Mathurin Fumery, Stephane Nahon, Stephane Nancey, Houda Camara, Laurent Peyrin-Biroulet","doi":"10.1177/17562848241265776","DOIUrl":null,"url":null,"abstract":"Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown.Objectives: This study investigated IBD patient satisfaction with approved adalimumab biosimilars and their originator.Design: In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with IBD across 45 centres affiliated with the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif who completed a satisfaction questionnaire comprising four items each rated by a 10-point scale.Methods: The differences in responses were performed using a one-way analysis of variance followed by Tukey's honest significant difference test.Results: The most commonly used drugs at inclusion were Humira® (436/941, 46.3%), Amgevita® (177/941, 18.8%) and Hulio® (105/941, 11.2%). The mean overall satisfaction rate with adalimumab was 8.5 (standard deviation 1.8). Overall satisfaction was significantly higher in patients treated with Humira (8.6 (1.5)), Hulio (8.6 (1.8)) or Amgevita (8.5 (1.4)) (p < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma® (9.0 (1.4)), Humira (8.9 (1.3)) and Hulio (8.9 (1.7)) (p < 0.05). A total of 299 patients (31.8%) described injection site reactions. In all, 223 patients (23.7%) reported being previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects.Conclusion: In this real-world setting, patients with IBD had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307357/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848241265776","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown.

Objectives: This study investigated IBD patient satisfaction with approved adalimumab biosimilars and their originator.

Design: In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with IBD across 45 centres affiliated with the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif who completed a satisfaction questionnaire comprising four items each rated by a 10-point scale.

Methods: The differences in responses were performed using a one-way analysis of variance followed by Tukey's honest significant difference test.

Results: The most commonly used drugs at inclusion were Humira^® (436/941, 46.3%), Amgevita^® (177/941, 18.8%) and Hulio^® (105/941, 11.2%). The mean overall satisfaction rate with adalimumab was 8.5 (standard deviation 1.8). Overall satisfaction was significantly higher in patients treated with Humira (8.6 (1.5)), Hulio (8.6 (1.8)) or Amgevita (8.5 (1.4)) (p < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma^® (9.0 (1.4)), Humira (8.9 (1.3)) and Hulio (8.9 (1.7)) (p < 0.05). A total of 299 patients (31.8%) described injection site reactions. In all, 223 patients (23.7%) reported being previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects.

Conclusion: In this real-world setting, patients with IBD had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device.

查看原文本刊更多论文

炎症性肠病患者对阿达木单抗的偏好：来自 GETAID 的全国性研究。

背景：目前有多种阿达木单抗制剂可用于炎症性肠病（IBD）患者。其满意度和耐受性的比较尚不清楚：本研究调查了IBD患者对已获批准的阿达木单抗生物仿制药及其原研药的满意度：在这项横断面研究中，我们纳入了隶属于Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif的45个中心的941名连续接受过阿达木单抗治疗的IBD患者，他们填写了一份满意度问卷，问卷由4个项目组成，每个项目均采用10分制评分：方法：采用单因素方差分析和Tukey诚实显著性差异检验对回答进行差异分析：纳入研究时最常用的药物是Humira®（436/941，46.3%）、Amgevita®（177/941，18.8%）和Hulio®（105/941，11.2%）。阿达木单抗的平均总体满意度为8.5（标准差为1.8）。接受Humira（8.6（1.5））、Hulio（8.6（1.8））或Amgevita（8.5（1.4））治疗的患者总体满意度明显更高（P ®（9.0（1.4））、Humira（8.9（1.3））和Hulio（8.9（1.7））（P 结论：在这一真实世界环境中，IBD患者对阿达木单抗治疗的满意度很高，但在总体满意度和对注射装置的满意度方面存在一些差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567